Javelin Biotech Strengthens Board with Robin Robinson as Drug Discovery Shifts Towards Human-Based Models
Javelin, a pioneer in human-centric preclinical drug discovery, today announced the appointment of Robin Robinson, PhD to its Board of Directors, effective February 2025. This strategic addition comes at a pivotal time, as the pharmaceutical industry accelerates its transition from traditional animal models to advanced human-based approaches in drug development.
